S1259
Clinical - Urology
ESTRO 2026
analyzed with a linear mixed model to assess the effects of treatment arm, time, and their interaction (arm × time), applying residual maximum likelihood estimation and assuming that any missing data were missing at random. Results: Median follow-up (FU) for PROs was 11.5 months. Demographic and PCa characteristics were evenly distributed across both arms. Neither IPSS nor EPIC- SF12 scores significantly differed between EHRT and AHRT, and neither significantly changed from baseline in either arm, at any point post-RT. MAX-PC scores did not significantly differ between the arms at any point post-RT, although the scores significantly decreased at nine and 15 months post-RT with EHRT (p=0.007 and 0.014), and at three months post-RT with AHRT (p=0.015) (Figure 1).
Conclusion: No significant difference was observed in any patient- reported outcome, and the largest changes from baseline occurred at the same post-RT time points, between EHRT and AHRT. These findings suggest little difference in patient-reported toxicity with AHRT, helping alleviate concerns regarding its toxicity. References: 1. Dasu A, et al. Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients. Acta Oncol. Nov 2012;51(8):963-74.2. Vogelius IR, et al. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys. Jan 1 2013;85(1):89-94.3. van As N, et al. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. NEJM. Oct 17 2024;391(15):1413- 1425. 4. Fransson P, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet. Feb 2021;22(2):235-245. Keywords: Stereotactic, Hypofractionation, Quality of Life Digital Poster 3365 omitting presacral irradiation in prostate cancer: patterns of failure and toxicity outcomes Mohammed Alwhaid 1 , Abdulrahman Aldakheel 1 , Lujain Bukhari 2 , Talal Alshehri 3 , AbdulAziz Al Hamad 4 1 Radiation Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. 2 Medical School, King Khalid University, Abha, Saudi Arabia. 3 Oncology, Armed Forces Hospital, Khamis Mushait,
EPIC urinary, bowel, sexual and hormonal scores did not significantly differ between the arms, and urinary scores did not significantly change from baseline in either arm, at any point post-RT. Bowel scores decreased significantly at 15 months post-RT (p=0.007) with EHRT, but not at any FU time point for AHRT. Sexual scores decreased significantly at 15 and nine months post-RT with EHRT (p=0.003) and AHRT (p=0.019), respectively. Hormonal scores decreased significantly at 15 months post-RT with both EHRT (p=0.033) and AHRT (p=0.049) (Figure 2).
Made with FlippingBook - Share PDF online